Fresenius Kabi And Vifor Ally In China

Joint Venture Will Be Based On Intravenous Iron Portfolio

Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.

Handshake_Flag_China
Fresenius Kabi and Vifor have agreed a Chinese joint venture • Source: Shutterstock

Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products. Fresenius said the joint venture would “combine Vifor Pharma’s leading intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s strong and long-year presence in the market to benefit both patients and the healthcare system in China,” providing patients with access to “vital blood management treatment.”

Although financial terms of the deal were not disclosed, the firms revealed that the joint company would be 55% owned...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business